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Abstract
Neurofibromatosis type 2 (NF2) is a tumour-prone disorder characterised by the development of
multiple schwannomas and meningiomas. Prevalence (initially estimated at 1: 200,000) is around 1
in 60,000. Affected individuals inevitably develop schwannomas, typically affecting both vestibular
nerves and leading to hearing loss and deafness. The majority of patients present with hearing loss,
which is usually unilateral at onset and may be accompanied or preceded by tinnitus. Vestibular
schwannomas may also cause dizziness or imbalance as a first symptom. Nausea, vomiting or true
vertigo are rare symptoms, except in late-stage disease. The other main tumours are schwannomas
of the other cranial, spinal and peripheral nerves; meningiomas both intracranial (including optic
nerve meningiomas) and intraspinal, and some low-grade central nervous system malignancies
(ependymomas). Ophthalmic features are also prominent and include reduced visual acuity and
cataract. About 70% of NF2 patients have skin tumours (intracutaneous plaque-like lesions or more
deep-seated subcutaneous nodular tumours). Neurofibromatosis type 2 is a dominantly inherited
tumour predisposition syndrome caused by mutations in the NF2 gene on chromosome 22. More
than 50% of patients represent new mutations and as many as one-third are mosaic for the
underlying disease-causing mutation. Although truncating mutations (nonsense and frameshifts) are
the most frequent germline event and cause the most severe disease, single and multiple exon
deletions are common. A strategy for detection of the latter is vital for a sensitive analysis.
Diagnosis is based on clinical and neuroimaging studies. Presymptomatic genetic testing is an
integral part of the management of NF2 families. Prenatal diagnosis and pre-implantation genetic
diagnosis is possible. The main differential diagnosis of NF2 is schwannomatosis. NF2 represents a
difficult management problem with most patients facing substantial morbidity and reduced life
expectancy. Surgery remains the focus of current management although watchful waiting with
careful surveillance and occasionally radiation treatment have a role. Prognosis is adversely affected
by early age at onset, a higher number of meningiomas and having a truncating mutation. In the
future, the development of tailored drug therapies aimed at the genetic level are likely to provide
huge improvements for this devastating condition.
Disease name and synonyms
Neurofibromatosis type 2(NF2), Bilateral acoustic neu-
rofibromatosis, Central neurofibromatosis. OMIM
#101000
Definition
Neurofibromatosis type 2 (NF2) is a dominantly inher-
ited tumour prone disorder characterised by the develop-
ment of multiple schwannomas and meninigiomas [1].
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The disease can be diagnosed when a pathogenic muta-
tion in the NF2 gene is identified or when the criteria in
table 1[1] are fulfilled.
Epidemiology
When using established clinical diagnostic criteria [1] and
based on mutations in the NF2 gene [2,3] assessment of
the frequency of NF2 in the population can be made. This
is complicated by the high rate of mosaicism [4]. There
have only been two epidemiological studies of NF2 one in
North West England [5,6], [Evans DG et al. Birth inci-
dence and prevalence of tumour prone syndromes: esti-
mates from a UK genetic family register service. Am J Med
Genet 2009. unpublished] and one in Finland [7]. The
incidence of NF2 was initially reported as 1:33–40,000
individuals in a 4 million population in England [5]. Dis-
ease prevalence was somewhat lower at 1: 200,000. How-
ever, a recent update suggests that the incidence may be as
high as 1:25,000 [6]. Disease prevalence has now risen to
around 1 in 60,000 due to earlier diagnosis and better sur-
vival due to improved treatment [Evans DG et al. Birth
incidence and prevalence of tumour prone syndromes:
estimates from a UK genetic family register service. Am J
Med Genet 2009. unpublished]. A lower incidence of 1 in
87,410 was reported in a 1.7 million population in Fin-
land [7].
Clinical description
NF2, in contrast to neurofibromatosis type 1 (NF1) is
characterised by the development of schwannomas, men-
ingiomas and ependymomas, with the great majority of
patients developing bilateral schwannoma involvement
of the superior vestibular branch of the eighth cranial
nerve [1]. Although the disease is still classified as "neu-
rofibromatosis", neurofibromas are relatively infrequent.
The first clear description of NF2 was in 1822 by Wishart
[8]. NF1 was fully delineated in the late nineteenth cen-
tury by von Recklinghausen. However, it was the eminent
Harvey Cushing, who described bilateral eighth nerve
tumours occuring as part of von Recklinghausen disease
in 1916 [9]. This description is largely responsible for the
confusion between the two conditions which continued
for many years. Indeed, the literature prior to 1985 has
many NF2 cases being described as part of von Reckling-
hausen disease, with bilateral vestibular schwannomas
(VS) being included in a major patient series [10].
The hallmark of NF2 is the development of bilateral VS.
VS usually present with hearing loss, tinnitus or imbal-
ance or a combination of the three symptoms. The other
main tumour features are schwannomas of the other cra-
nial, spinal and peripheral nerves; meningiomas both
intracranial (including optic nerve meningiomas) and
intraspinal; and some low-grade central nervous system
(CNS) malignancies (ependymomas and gliomas). Four
large clinical studies have now confirmed this clinical pic-
ture [1,11-13] (Table 2). Individuals may present with cra-
nial meningiomas or a spinal tumour long before the
appearance of a VS.
The majority of individuals with NF2 present with hearing
loss, which is usually unilateral at time of onset. The hear-
ing loss may be accompanied or preceded by tinnitus. VS
may also cause features such as dizziness or imbalance as
the first symptom. Nausea, vomiting or true vertigo are
rare symptoms except in late stage disease.
A significant proportion of cases (20–30%) present with
symptoms from an intracranial meningioma (headaches,
seizures), spinal tumour (pain, muscle weakness, paraes-
thesia), or cutaneous tumour [1,11-13]. Indeed, the first
sign of more severe multi-tumour disease in early child-
hood is often a non-8th nerve tumour (including a cutane-
ous tumour), or an ocular presentation [14]. Adult
presentation is thus quite different to paediatric presenta-
tion, in which VS accounts for as little as 15–30% of initial
symptoms. There also appears to be a tendency to monon-
europathy, particularly affecting the facial nerve causing a
Bell's-like palsy, which does not fully recover years before
the detection of a VS. Some children present with a polio-
like illness with wasting of muscle groups in a lower limb,
which again does not fully recover. In adulthood, a more
generalised symptomtatic severe polyneuropathy occurs
in about 3–5% of patients, often associated with an
"onion bulb" appearance on nerve biopsy [1]. This can
progress, leading to severe muscle wasting and even death.
However, around 40% of patients will show evidence of
polyneuropathy on nerve conduction studies [15].
Table 1: Diagnostic criteria for Neurofibromatosis type 2 (these include the NIH criteria with additional criteria)
Main criteria Additional criteria
Bilateral vestibular schwannomas (VS) or family history of NF2 plus Unilateral VS plus any two of: meningioma, glioma, neurofibroma, 
schwannoma, and posterior subcapsular opacities
1) Unilateral VS or or
2) Any two of: meningioma, glioma, neurofibroma, schwannoma, 
posterior subcapsular lenticular opacities
Multiple meningioma (two or more) plus unilateral VS or any two of: 
glioma, neurofibroma, schwannoma, and cataract
NF2 – Neurofibromatosis type 2; NIH – National Institutes of Health; VS – vestibular schwannomasOrphanet Journal of Rare Diseases 2009, 4:16 http://www.ojrd.com/content/4/1/16
Page 3 of 11
(page number not for citation purposes)
Ophthalmic features are also prominent in NF2. Patients
often suffer from reduced visual acuity of various causes.
Between 60–80% of patients have cataracts [1,10,11],
which are usually presenile posterior subcapsular lenticu-
lar opacities that rarely require removal. However, cortical
wedge opacities may be present from near birth. Optic
nerve meningiomas can cause visual loss in the first years
of life and extensive retinal hamartomas can also affect
vision. Misdiagnosis of both of these abnormalities as
retinoblastoma has led to the eye being removed in the
first few years of life.
The skin is a useful aid to diagnosis, but cutaneous fea-
tures in NF2 are much more subtle than in NF1. About
70% of NF2 patients have skin tumours, but only 10%
have more than ten skin tumours. The tumours appear to
be of at least three different types. The most frequent type
is a plaque-like lesion, which is intra-cutaneous, slightly
raised and more pigmented than surrounding skin, often
with excess hair. More deep-seated subcutaneous nodular
tumours can often be felt, sometimes on major peripheral
nerves. These tumours occur as a fusiform swelling of the
nerve with thickened nerve palpable on either side. There
are also occasional intracutaneous tumours similar to
those in NF1. The great majority of these tumours are
schwannomas, but occasional definite neurofibromas do
occur.
Etiopathogenesis
NF1 and NF2 were eventually recognised as separate
genetic and clinical diseases with the localisation of the
respective genes to chromosome 17 and 22 [16,17]. This
was followed by the formal clinical delineation at a
National Institutes of Health (NIH) consensus meeting in
the USA in 1987 [18]. It is now clear that NF2 is a geneti-
cally homogeneous condition, with no evidence for
another genetic cause of classical NF2 (bilateral VS).
Seizinger et al. were the first to show loss of constitutional
heterozygosity of chromosome 22, with DNA markers lost
in tumours from a patient with NF2 [19]. As such NF2 was
one of the first inherited tumour prone disorders to be
localised to a specific genetic location. Linkage studies
then confirmed that all affected members of the large fam-
ily carried the same copy of chromosome 22q. The NF2
gene was then isolated by the simultaneous discovery of
constitutional and tumour deletions in a gene coding for
a cell membrane-related protein, which has been termed
merlin or schwannomin by the two groups who isolated
it [2,3].
Table 2: Clinical characteristics of Neurofibromatosis type 2 patients in four studies
Characteristic Study
Kanter et al. [11] Evans et al. [1] Parry et al. [12] Mautner et al. [13]
Number of cases 73 120 63 48
Number of families 17 75 32 44
Sporadic cases 0 45 17 44
Mean age at onset (years) 20 (of 59) 22 20 17
Intracranial meningiomas (%) 18 45 49 58
Spinal tumours (%) NA 26 67 90
Skin tumours (%) 32 (of 73) 68 (of 100) 67 64
Café-au-lait macules (%) 42 (of 31) 43 (of 100) 47 NA
Cataract (%) NA 38 (of 90) 81 62
Intracranial astrocytoma (%) NA 4.1 1.6 NA
Ependymoma (%) NA 2.5 3.2 6
Optic sheath meningioma (%)1 NA 4.1 4.8 8
1In Mautner et al., the frequency of optic nerve sheath tumours is for all histological types (i.e., schwannomas and meningiomas).Orphanet Journal of Rare Diseases 2009, 4:16 http://www.ojrd.com/content/4/1/16
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Constitutional mutations
Standard mutation techniques, such as Single Strand Con-
formational Polymorphism (SSCP) analysis or Denatur-
ing Gradient Gel Electrophoresis, detected between 35%
and 66% of pathogenic mutations [20-23]. The majority
of these mutations were truncating mutations, leading to
a smaller and probably non-functional protein product.
Early studies suggested that missense mutations (which
result in a complete protein product) and large deletions
(which result in no protein product) both caused predom-
inantly mild phenotypes. Larger studies of detailed geno-
type/phenotype correlations in multiple families have
confirmed this finding [21-26]. Phenotype is more varia-
ble in patients with splice-site mutations, with milder dis-
ease in patients with mutations in exons 9–15 [26,27].
Definitive evidence from effects on survival have been
established with missense mutation patients having statis-
tically greater survival than nonsense and frameshift
mutations [26]. As in other tumour prone disorders the
frequency of large genomic rearrangements did not
become apparent until some time after the gene was
cloned, due to the poor availability of methods to allow
routine clinical screening for their presence. About half of
these are detectable with standard cytogenetic analysis
with FISH [28]. A small number of constitutional abnor-
malities such as chromosome translocations and ring 22
would still need a cytogenetic analysis to confirm their
presence. The majority of large scale rearrangements are
now routinely detected by Multiplex Ligation-dependant
Probe Amplification (MLPA) and are known to account
for around 15% of NF2 germline aberrations [28,29]. The
commonest of this class of mutations is a deletion of the
NF2 promoter, exon 1 and most of intron 1 and deletions
of the whole gene, indeed combined these two account
for over half of all MLPA abnormalities (Table 3). The dif-
fering frequency of the various types of NF2 mutation
between familial, sporadic and mosaic cases can be seen
in Table 4. This represents the output from one centre
dedicated to whole gene analysis with the great majority
of patients having been screened by a technique capable
of the detection of large deletions or duplications. More
extensive lists of NF2 mutations described worldwide are
available online and in recent reviews [30-32], but these
are less likely to reflect the true ratios of different classes
of mutations, as a variety of different techniques have
been used. The sensitivity of genetic testing using
sequence analysis and MLPA can be derived from column
1 (Table 1). Ninety-three per cent of mutations have been
identified in the second generation of NF2 families. Of the
missing eight families six have been subjected to more
detailed analysis including RNA analysis. Two putative
splicing variants deep in the introns have been identified
based on Protein Truncation Testing and intronic
sequencing (Messaien L, personal communication), but
no other mutations have been found.
A considerable proportion of NF2 patients, particularly
milder cases, have mosaic disease, in which only a propor-
tion of cells contain the mutated NF2 gene. The initiating
mutation occurs after conception, leading to two separate
cell lineages. The proportion of cells affected depends on
how early in development the mutation occurs. Recent
evidence suggests that up to 20–30% of NF2 cases without
a family history of the disease are mosaic, carrying the
mutation in too small a proportion or none of their lym-
phocytes to be detected from a blood sample [4,33-35].
This accounts for the milder disease course in many indi-
viduals with unfound mutations, and since only a subset
of germ cells (or none) will carry the mutation, there is
less than a 50% risk of transmitting the disease to their
offspring. However, if an offspring has inherited the
mutation, they will have a typical phenotype and usually
be more severely affected than their parent, since the off-
spring will carry the mutation in all of their cells. One of
the features that suggested that mosaicism existed in NF2
was that NF2 mutations were harder to find in blood in
isolated non inherited cases than in patients who had
inherited the disease from an affected parent. Mosaicism
may be particularly likely in NF2 if the tumours are pre-
dominantly on one side of the body. The mosaic muta-
tion can be detected by analysing tumour material from
an affected individual. If an identical mutation is found in
two tumours from that individual, their offspring can be
tested for the presence of the mutation. Also when two
alterations, either: two mutations or one mutation plus
one allele loss, are found in on tumour, one of these must
be the constitutional one. Thus offspring can be tested for
both abnormalities and potentially exclude inheriting
NF2.
C > T transitions leading to a nonsense mutation are the
most common mutations in the NF2 gene [30-32]. These
account for the only significant variation in mutation fre-
quency across the NF2 gene apart from the lack of muta-
tions in exons 16 and 17 and a relatively low frequency in
exon 9 [30].
Somatic mutations
There are notable similarities, but also differences
between the distribution and type of germline and
somatic NF2 mutations. Among germline mutations in
classic NF2, nonsense mutations are more common than
frameshift mutations by a ratio of 1.3:1, but this ratio is
reversed for somatic mutations [36]. In both situations
NF2  nonsense mutations, C > T transitions in CGA
codons and non-CGA codons are the most common sin-
gle base-pair transitions. However there is a marked
absence of mutations in exons 14 and 15 in sporadic men-
ingioma. One recently reported phenomenon is the
increasing drift from nonsense mutations in the germline
and early somatic mutations to a predominance ofOrphanet Journal of Rare Diseases 2009, 4:16 http://www.ojrd.com/content/4/1/16
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frameshift mutations in the tumours of older patients
with vestibular schwannoma [36]. This is likely to be due
to a deficiency in certain DNA repair pathways in older
patients [36].
Although it is thought that effectively all schwannomas
require inactivation of the NF2 gene, no reports apart
from those studying NF2 protein have confirmed a 100%
knock out of both copies of the NF2 gene. This is likely to
be due to diversity of mechanisms that inactivate the gene.
The standard approach of mutational analysis and Loss of
Constitutional Heterozygosity (LOH) on tumours will
detect involvement of NF2 in about 80–90% of schwan-
nomas, but both copies can only be confirmed as affected
in about 50–60% of cases. The mechanism of LOH is also
not straightforward, whilst most cases involve loss of
Table 3: MLPA abnormalities in 62 unrelated families
MLPA abnormality Number of occasions (mosaic)
Exon 1-intron1 (deletes intronic CA repeat) 18 (3)
Whole gene (exons 1–17) deletion 16 (2)
Exons 5–17 deletion 3 (2)
Exons 2–3 deletion 2
Exons 2–10 deletion 2
Exons 13–15 deletion 1
Exons 1–16 deletion 2 (1)
Exons 1–10 deletion 3 (1)
Exons 1–3 deletion 1
Exons 1–4 deletion 2 (1)
Exons 1–2 deletion 1 (1)
Exons 15–17 deletion 1
Exons 8–17 deletion 1
Exons 8–15 deletion 1
Exon 3 deletion 1
Exon 7 deletion 1
Exon 5 deletion 1
Exons 12–14 duplication 1
Exons 10–16 duplication 1
Exon 2 deletion 1
Exon 8 deletion 1
Exons 2–4 deletion 1
MLPA- Multiplex Ligation-dependant Probe AmplificationOrphanet Journal of Rare Diseases 2009, 4:16 http://www.ojrd.com/content/4/1/16
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chromosome 22 or at least the long arm, a proportion are
now known to be due to mitotic recombination with
essentially two identical copies of a mutated NF2 gene
and distal 22q [37]. This mechanism is now thought to be
a primary cause of NF2 inactivation in schwannomatosis.
It is now known that between 20–40% of sporadic
schwannomas are inactivated by NF2 methylation [38,39]
and in a similar fashion to TP16 this could involve both
copies of NF2 and explain why some tumours do not har-
bour identifiable point mutations or LOH. Approximately
60% of sporadic meningiomas have NF2 gene involve-
ment and promoter methylation again plays a significant
role [40].
Diagnosis
The Manchester (modified NIH) diagnostic criteria for
NF2 are shown in Table 1. The original NIH criteria have
been expanded to include patients with no family history
who have multiple schwannomas and or meningiomas,
but who have not yet developed bilateral 8th  nerve
tumours. Patients who have asymmetric involvement are
likely to be mosaic [41]. At very young ages (< 18 years)
individuals presenting with an apparently isolated menin-
gioma [14] or vestibular schwannoma [42] are have a
20% and 10% likelihood respectively of developing NF2.
However after 20 years of age this rate drops dramatically
and the diagnosis becomes very unlikely after 30 years of
age [42].
Diagnostic methods
￿ Clinical and family history
￿ Examination including cutaneous and ophthalmic
(Slit lamp)
￿ Craniospinal MRI
￿ Molecular analysis
Differential diagnosis
The main differential diagnosis of NF2 is schwannomato-
sis and some patients with multiple non cranial schwan-
nomas turn out to have mosaic NF2 [34,35]. However,
patients fulfilling the most sensitive Manchester criteria
are unlikely to be misclassified [43].
Antenatal diagnosis and genetic counselling
NF2 is an autosomal dominant disease with usually a
50% risk of transmission from an affected individual to
their offspring. This was first confirmed in a large family
reported by Gardner and Frazier in 1930. 50–60% of
patients have no family history and represent de novo
mutations in the NF2 gene [1-3]. Individuals who inherit
a pathogenic mutation in the NF2 gene will almost always
develop symptoms by 60 years of age [7]. Exceptionally,
patients particularly in the pre MRI era will have not been
diagnosed in their lifetime. Although the transmission
rate is 50% in the second generation and beyond, the risk
of transmission in an apparently isolated patient with
NF2 is less than 50% due to mosaicism [4].
Because detection of tumours at an early stage is effective
in improving the clinical management of NF2, pre-symp-
Table 4: Mutations identified in 529 families with Neurofibromatosis type 2 in the Manchester (UK) genetics laboratory
Type of mutation Detection in 2nd generation 
(n = 108)
Detection in sporadic non mosaic 
patients (% non mosaic)
Mosaic mutations (% of mosaic) Total
Splice site 35 (32%) 43 (22%) 3 (4%) 80 (15%)
MLPA positive 23 (20%) 28 (14%) 11 (15%) 62 (12%)
FSD 18 (17%) 36 (18%) 20 (26%) 74 (13%)
Nonsense 16 (15%) 67 (35%) 28 (37%) 111 (22%)
Missense 7 (6%) 5 (3%) 1 (1%) 13 (2.5%)
FSI 3 (3%) 11 (7%) 6 (8%) 20 (4%)
IFD 1 (1%) 1 3 (4%) 5 (1%)
Ring 22 0 0 3 (4%) 3
Not found 7 (7%) 230 (55%) 158 166/529 (31%)
Total 108 191/421 (45%) 72 529Orphanet Journal of Rare Diseases 2009, 4:16 http://www.ojrd.com/content/4/1/16
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tomatic genetic testing is an integral part of the manage-
ment of NF2 families. Once a mutation has been
identified in an affected individual, a 100% specific test is
available for the family. However, mutation screening
may not reveal the causative mutation. Predictive diagno-
sis by linkage analysis using intragenic markers or markers
flanking the NF2 gene is also possible in the great majority
of families with two or more living affected individuals. In
the absence of a genetic test a cumulative age at onset
curve [44] can be used. Age at onset curves aid genetic
counselling; for example, the risk of having inherited NF2
for an asymptomatic at-risk individual 25 years of age,
prior to screening, drops to 25%. The risk to an unaffected
30 year old with a normal scan would be < 10%. Tumour
analysis plays a vital role in providing genetic testing for
the offspring of sporadic patients. Indeed analysis should
if possible first be carried out on tumour so that a targeted
approach can be used on the blood sample. If both muta-
tional events are identified in the NF2 gene in a tumour
and neither is present in the blood the patient must be
mosaic for one of these mutations [33-35,45,46]. Even if
only LOH is identified this still allows exclusion of NF2 in
50% of offspring if they can be shown to have inherited
the allele "lost" in the tumour [35,46]. At-risk individuals
who are shown not to have inherited the mutated NF2
gene do not need further follow-up.
Even in the absence of identifying a mutation the residual
risk of NF2 can be substantially reduced in the child of an
apparently isolated case. In particular patients presenting
with asymmetric disease over 40 years of age with negative
mutation analysis in blood would have a very low chance
of transmitting NF2 to their children (Table 5).
Because of the severity of NF2 there is a demand for pre-
natal diagnosis and pre-implantation genetic diagnosis.
Use of the techniques above means that this is possible in
the great majority of families.
Screening protocol
Children of affected patients should be considered to be
at 50% risk of NF2 and screening for NF2 can start at birth.
Cataracts can affect vision in early life and other tumour
implications are present in the first ten years of life, partic-
ularly cranial meningiomas. Formal screening for VS
should start at ten years, as it is rare for tumours to
become symptomatic before that time even in severely
affected families. Annual audiological tests including
auditory brainstem response are still a useful adjunct to
MRI [44]. Surgery is unlikely to be more successful for
tumours < 6 mm than for tumours sized 6 mm, but VS
growth is higher in younger patients, so for asymptomatic
at-risk individuals without tumours, MRI screening every
two years for those < 20 years old and every 3–5 years for
those age > 20 years should be sufficient. The initial MRI
scan could be at around 12 years of age, or 10 years in
severely affected families. Once tumours are present, MRI
screening should probably be at least annual. Spinal
tumours are seen in 60–80% of NF2 patients on MRI [47-
50]. While only 25–30% of patients with spinal tumours
require a spinal operation from a symptomatic tumour, a
full annual neurological examination is probably a wise
precaution with Spinal MRI only every 3 years or if there
Table 5: Transmission risks to offspring for isolated cases of Neurofibromatosis type 2 before and after negative mutation testing. 
Number PRE testing Mosaic inferred PRE testing Transmission 
risk
POST genetic negative 
testing in blood Mosaic 
inferred
POST genetic negative testing 
in blood Transmission risk
< 20 BVS 85 12% 45% 46% 30% 1 in 3
< 20 UVS 21 42% 33% 87% 11% 1 in 9
20–29 BVS 67 27% 36% 78% 16% 1 in 6
20–29 UVS 27 78% 19% 97% 8% 1 in 12
30–39 BVS 54 50% 28% 88% 11% 1 in 9
30–39 UVS 19 85% 12% 98% 6% 1 in 16
40+ BVS 53 63% 22% 93% 9% 1 in 11
40+ UVS 34 90% 10% 99% 5% 1 in 20
Results are based of outcomes of testing in first affected family members and on age at onset and laterality of presentation with vestibular 
schwannomas (VS).
BVS – presentation with bilateral VS; UVS – initial presentation with unilateral VSOrphanet Journal of Rare Diseases 2009, 4:16 http://www.ojrd.com/content/4/1/16
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are new symptoms. If no tumours are present on the ini-
tial scan a further scan 5–10 years later may be reasonable.
In most families it is now possible to develop a genetic test
so that screening can be targeted to affected individuals
only. Identifying the affected patient's mutation not only
allows testing of at risk relatives, but may also give impor-
tant indicators as to the patient's own prognosis. As 25–
30% of NF2 patients are mosaic frozen tumour should be
taken at operation (with patient consent) for genetic tests.
NF2 management
NF2 presents many difficult management dilemmas. The
mainstay of management of NF2 is surgical removal of
symptomatic cranial and spinal tumours. The timing of
removal of vestibular schwannomas is a more difficult
area. Surgical results are certainly far better when man-
aged by an experienced team [50-52]. There is clear evi-
dence of a reduction in mortality with a significantly
increased life expectancy for NF2 patients managed at 3
specialty centres in the UK (OR 0.34) [53]. It is important
to balance the use of microsurgery and radiation treat-
ment, which can have a role in patients who have particu-
larly aggressive tumours, or who are poor surgical risks, or
who refuse surgery. Teams experienced in the positioning
of brainstem implants can offer partial auditory rehabili-
tation to those who are deaf, although results are still
behind those achievable for cochlear implants. Although
the cochlear nerve may be left initially intact after surgery
its blood supply may be damaged, nonetheless a few
patients can be rehabilitated successfully with a cochlear
implant.
Outcomes
Even with improvements in microsurgery and with use of
radiation therapy, the great majority of individuals with
NF2 become completely deaf. The tumours in NF2 are
more difficult to treat than those of sporadic unilateral VS,
as NF2 VS are often multifocal, appearing "like a bunch of
grapes" around the vestibular nerve in particular. There is
evidence for a histological difference, with NF2 VS being
more lobular and less vascular then their sporadic coun-
terparts [54]. This leads to a greater risk of facial nerve
damage in NF2. Loss of facial nerve function is one of the
most feared aspects of the condition for many sufferers,
although in good surgical hands this complication is now
much less common [50,52]. Patients may also be severely
disabled by a combination of poor balance, visual prob-
lems and weakness due to spinal tumours. Indeed, many
NF2 patients become wheelchair-bound in early adult-
hood. Many patients with multi-tumour disease die in
their twenties and thirties. In view of the multiplicity of
problems affecting many patients it is strongly recom-
mended that NF2 patients are managed by a multidiscipli-
nary team in specialist centres [52].
Specialty centres
A typical NF2 specialist centre will require involvement of
a number of key staff members.
Permanent clinic staff
Neurosurgeon, Otolaryngologist, physician (neurologist/
geneticist), clinic nurse/patient link worker and a dedi-
cated clinic secretary.
Clinic equipment: lightwriter/pallantype/voice activated
software.
In order to minimise patient visits morning scanning with
lunchtime radiological review and an afternoon clinic is
preferable.
Each clinic should have access to a named
Neuroradiologist, ophthalmologist, peripheral nerve sur-
geon, plastic surgeon, neurologist/geneticist (if not
involved in main clinic), hearing therapist, physiothera-
pist, paediatrician.
Patients should be given the option of a radiation therapy
opinion, which will only be available at a few centres.
Managing affected children
NF2 is being recognised more and more frequently in
childhood often before VS have developed. Recognition
of the more severe disease course with early presentation
and the more atypical features such as mononeuropathy
are important.
Surgery
VS in NF2 are more difficult to treat than those of sporadic
unilateral VS because NF2-related VS are often multifocal
in the eighth nerve complex, and the potential for associ-
ated facial nerve schwannomas. Surgery to remove VS in
NF2 almost always leads to total deafness with loss of the
cochlear nerve. Despite the great improvement in VS sur-
gery over the last three decades, facial nerve damage and
other adverse outcomes remain a real possibility during
tumour removal, especially in the hands of less experi-
enced VS surgeons. Facial weakness may threaten the
health of the eye as a result of loss of the protective blink
reflex. and as the lacrimal gland is also supplied by the
facial nerve the loss of tear production will increase this
risk. If facial nerve damage coexists with loss of corneal
sensation from damage to the trigeminal nerve then the
eye becomes exceptionally vulnerable to corneal ulcera-
tion and blindness.
The cornerstone of modern NF2 management is conserva-
tion of function, and the maintenance of "quality of life".
The mere presence of a tumour is not an indication for its
removal. Serious thought must be given to the benefitsOrphanet Journal of Rare Diseases 2009, 4:16 http://www.ojrd.com/content/4/1/16
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that are sought and the risks and complications of the sur-
gery, and the treatment must be tailored to the needs of
the individual patient [52]. Attempts at hearing preserva-
tion surgery should be limited to experienced centres who
can offer a realistic chance of maintaining both the coch-
lear nerve, but also cochlea function. If hearing is lost after
apparent cochlear nerve preservation the patient may still
be suitable for a cochlear implant. In many if not most
instances the best policy will be to observe VS to decide on
the best time to balance surgical morbidity against the
almost inevitable loss of hearing.
The principle of minimal interference for VS applies
equally to schwannomas on other cranial nerves, to
intracranial meningiomas, and to spinal tumours. It is
very uncommon to have to remove a schwannoma grow-
ing on a cranial nerve other than the eighth because these
tumours appear to have a much slower growth pattern
than NF2 VS. Spinal tumours are mostly considered for
excision if they are clearly producing symptoms or physi-
cal signs. In the absence of any dramatic growth of
tumours, the head should be scanned every year and the
spine every 3 years.
Radiation therapy
It is important to balance the use of microsurgery and
radiation treatment, which has a role in patients who are
poor surgical candidates, or who refuse or wish to avoid
surgery because of its associated risks. Radiation therapy
should be mentioned as a management option, even if the
tumour is larger than the size criterion for treatment. The
upper limit of size for radiotherapy is generally a maxi-
mum intracranial diameter of 3 cm [55]. The patient
should be aware of the management options even if the
tumour is not suitable for a particular treatment modality.
In NF2 cases selected for radiosurgery tumour control
rates are of the order of 50%, with 40% retaining pre-treat-
ment hearing for at least 3 years [56]. This is nonetheless
substantially worse than for sporadic vestibular schwan-
nomas.
Surgeons should use clinical judgement as to when to rec-
ommend radiation therapy [52]. Follow-up for life with
interval scanning is necessary, although this would be
required for NF2 anyway. Patients should be made aware
of the variable reported outcomes of the treatment and
the risk of the radiation-induced malignant change, which
has been reported disproportionately more in NF2 than
sporadic patients [57,58]. The tumour may also be more
difficult to excise after radiotherapy, and that reported
facial nerve outcomes after surgery following stereotactic
radiation therapy are frequently poor [59].
New therapies
The NF2 protein appears to impact on multiple intracellu-
lar signalling pathways. These pathways include the PI3-
kinase/Akt, Raf/MEK/ERK and mTOR pathways [60]. In
particular, studies using NF2-derived tumour tissue reveal
elevated levels of phosphorylated Akt. More recently, Akt-
dependent phosphorylation of Merlin on 2 residues (Thr-
230 and Ser-315) has been shown to target Merlin for
ubiquitin-dependent degradation. Although no PI3
kinase or Akt inhibitors have yet been approved for treat-
ment, there are multiple compounds in development –
primarily for oncology indications. The Raf/MEK/ERK
pathway has been implicated in NF2 tumorigenesis in
part through identification of elevated levels of phospho-
ERK and phospho-MEK.
The progress being made in cellular research especially
with regard to pathways in which the NF2 gene product
interacts raises the hopes of targeted therapy. Targeting the
ERK1/, AKT, integrin/focal adhesion kinase/Src/Ras sign-
aling cascades, PDGFRbeta, phosphatidylinositol 3-
kinase/protein kinase C/Src/c-Raf pathway, VEG-F and
other pathways [60,61] means that drugs such as avastin,
elotinib [62], lapatinib and sorafenib [63] may well bear
fruit.
Prognosis
NF2 remains a life limiting and life spoiling condition.
Patients diagnosed prior to 1990 had only a 15 year life
expectancy from diagnosis [1,64]. Improvement in man-
agement and early diagnosis are improving these out-
comes but many people with NF2 still die very young.
Prognosis is adversely affected by early age at onset,
number of meningiomas and having a truncating muta-
tion [52].
Unresolved questions
1. What is the most appropriate molecular/cell biolog-
ical target(s) for therapy
2. What are the long term safety issues of radiation
treatments and does fractionated radiotherapy offer
advantages over sterotactic or gamma knife treatment
Conclusion
NF2 remains a condition that is life spoiling and life lim-
iting. Multidisciplinary management with early diagnosis
are mainstays of management. Hopefully new targeted
therapies will revolutionise the outcomes in this condi-
tion.
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